Citi raises Ligand Pharma price target to $397 after royalty deal

September 23, 2026 6:16 AM

Citi analyst Yigal Nochomovitz raised the price target on Ligand Pharmaceuticals (NASDAQ: LGND) to $397 from $390, while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found